AstraZeneca hails Imfinzi green light ahead of New York trading debut
I'm PortAI, I can summarize articles.
AstraZeneca has received a positive recommendation from the EU for its drug Imfinzi, in combination with chemotherapy, for treating early-stage gastric cancers. The recommendation is based on significant trial results showing reduced risks of progression and death. Additionally, AstraZeneca's shares will debut on the New York Stock Exchange, aligning its listings across major exchanges. The company has committed to a $50 billion investment in US manufacturing and R&D, and has secured agreements to lower drug costs and delay tariffs, enhancing its operational capabilities in the US.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments